US 12,280,174 B2
Extracellular matrix material
Elena Garcia-Gareta, Middlesex (GB); and Nupur Kohli, Middlesex (GB)
Assigned to Raft Enterprises Ltd.
Appl. No. 16/333,558
Filed by Raft Enterprises Ltd., Middlesex (GB)
PCT Filed Sep. 20, 2017, PCT No. PCT/GB2017/052796
§ 371(c)(1), (2) Date Mar. 14, 2019,
PCT Pub. No. WO2018/055361, PCT Pub. Date Mar. 29, 2018.
Claims priority of application No. 1615972.5 (GB), filed on Sep. 20, 2016.
Prior Publication US 2019/0262502 A1, Aug. 29, 2019
Int. Cl. A61L 27/26 (2006.01); A61L 27/22 (2006.01); A61L 27/32 (2006.01); A61L 27/56 (2006.01)
CPC A61L 27/26 (2013.01) [A61L 27/225 (2013.01); A61L 27/32 (2013.01); A61L 27/56 (2013.01); A61L 2430/02 (2013.01)] 22 Claims
 
1. An extracellular matrix material, comprising:
a cross-linked scaffold comprising fibrin or fibrinogen, and a bulking agent, wherein the fibrin or fibrinogen and the bulking agent are covalently cross-linked, and the bulking agent is covalently cross-linked to the fibrin or fibrinogen; and
a ceramic deposited on the scaffold.